SG/CALL/MODERNA/160/0.1/17.01.25 | Delayed Deutsche Boerse AG 18:56:55 13/05/2024 BST | ||
| 1.13 EUR | +37.80% |
|
| Current month | +5.13% | ||
| 1 month | +12.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/05/24 | 1.13 | +37.80% | 0 |
| 10/05/24 | 0.82 | -18.00% | 0 |
| 09/05/24 | 1 | +3.09% | 18,000 |
| 08/05/24 | 0.97 | +3.19% | 0 |
| 07/05/24 | 0.94 | -3.09% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 13, 2024 at 06:56 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SQ860S |
| ISIN | DE000SQ860S0 |
| Date issued | 16/02/2023 |
| Strike | 160 $ |
| Maturity | 17/01/2025 (249 Days) |
| Parity | 10 : 1 |
| Emission price | 5.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.15 € |
|---|---|
| Lowest since issue | 0.3 € |
| Spread | 0.01 € |
| Spread % | 0.92% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.3
USD
Average target price
139.4
USD
Spread / Average Target
+18.79%
- Stock Market
- Warrants
- Warrant
